A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Hypertensive toxicity of thyrosine kinase inhibitors; Friend or Foe?
2021
Annals of Clinical Hypertension
Preserved Fulltext
Tyrosine kinase inhibitors (TKIs) are widely used in Oncology practice. Hypertension may develop during cancer treatment and TKIs are well known drugs that are associated with drug related hypertensive toxicity. TKI related hypertensive toxicity is not always the indicator of worse clinical outcomes and it may be the sign of treatment efficacy.
doi:10.29328/journal.ach.1001025
fatcat:2fj6jiag45cnfpv4nghueetowe